Pirkko Kellokumpu‐Lehtinen

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Sherene Loi, Stefan Michiels, Roberto Salgado et al. · Annals of Oncology · 2014 · 1.3K citations

Medicine, Immunology, Oncology +15

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

Jonas Bergh, Tom Wiklund, Björn Erikstein et al. · The Lancet · 2000 · 342 citations

Medicine, Oncology, Pharmacology +17

Biomarker evidence of DNA oxidation in lung cancer patients: association of urinary 8‐hydroxy‐2′‐deoxyguanosine excretion with radiotherapy, chemotherapy, and response to treatment

Marina Erhola, Shinya Toyokuni, K. Okada et al. · FEBS Letters · 1997 · 265 citations · Full text

Medicine, Cancer Biology, Oncology +13

Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in <i>HER-2/neu</i>–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401

Minna Tanner, Jorma Isola, Tom Wiklund et al. · Journal of Clinical Oncology · 2006 · 255 citations · Full text

Medicine, Oncology, Pharmacology +16